AgingResearch.NewsJoin free

National Heart, Lung, and Blood Institute, National Institutes of Health, U.S. Department of Health and Human Services

Company

National Heart, Lung, and Blood Institute, National Institutes of Health, U.S. Department of Health and Human Services develops 2 assets, the furthest in phase 1 (ACI-24 in Down syndrome). Mostly vaccine and small molecule acting on APP, proteostasis and BCHE.

2
Assets
Furthest stage
Phase 1
29
Trials
0
Signals

Pipeline

2

  • ACI-24

    Liposomal anti-amyloid-beta vaccine designed to elicit antibodies against amyloid-beta to prevent or clear plaques

    Phase 1, Vaccine, APP, Proteostasis, Down syndrome, Partner

  • bisnorcymserine

    Selective butyrylcholinesterase inhibitor

    Phase 1, Small molecule, BCHE

Full company profiles: pipeline, trials, funding and people.

See Pro

Subsidiaries

1

In the full profile

  • Evidence behind the mechanisms3
  • Trials513
  • Signals1
  • Similar companies6

Intelligence